MWNA
BEAM icon

Marshall Wace North America’s Beam Therapeutics BEAM Stock Holding History

Marshall Wace North America’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$12.5M Buy
+143,500
New +$14.4M 0.05% 312
2020
Q4 		– Sell
-264,116
Closed -$6.5M – 1314
2020
Q3 		$6.5M Sell
264,116
-13,908
-5% -$345K 0.04% 351
2020
Q2 		$7.78M Buy
278,024
+26,262
+10% +$566K 0.05% 303
2020
Q1 		$4.53M Buy
+251,762
New +$5.47M 0.03% 335

Other funds holding BEAM

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Marshall Wace North America's BEAM Position: Q3 2021 in Review

Marshall Wace North America opened a new position in Beam Therapeutics (BEAM) in Q3 2021: 143,500 shares worth $12.5M. The stake represents 0.05% of the portfolio and ranks #312 among its holdings. This is a return to the name: Marshall Wace North America previously reported a position in BEAM as recently as Q3 2020.

Marshall Wace North America first reported a position in BEAM in Q1 2020 and has held it in 4 quarters since. 231 funds tracked by Wall St. Rank hold BEAM as of Q3 2021.

  • Marshall Wace North America held 143,500 shares of Beam Therapeutics worth $12.5M as of Q3 2021.
  • Beam Therapeutics was a new Marshall Wace North America position in Q3 2021.
  • Beam Therapeutics made up 0.05% of Marshall Wace North America's portfolio in Q3 2021, its #312 holding.
  • Marshall Wace North America first reported a position in Beam Therapeutics in Q1 2020 and has held it in 4 quarters since.
  • 231 funds tracked by Wall St. Rank held Beam Therapeutics as of Q3 2021.

Based on Marshall Wace North America's 13F filing for Q3 2021, filed 15 Nov 2021.